Array Biopharma, Inc. (ARRY) Reports Q2 Loss of 17c/Share
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.06 -4.25%
Revenue Growth %: -16.4%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -16.4%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.10 better than the analyst estimate of ($0.27).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Array Technologies (ARRY) to Neutral
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
- Children's Place (PLCE) Misses Q2 EPS by 20c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
